Clinical Trial: Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Study Status: Enrolling by invitation
Recruit Status: Enrolling by invitation
Study Type: Interventional
Official Title: Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever)
Brief Summary: To provide an intravenous ribavirin therapeutic option for patients with a probable or suspected case of viral hemorrhagic fever, specifically Crimean-Congo hemorrhagic fever or Lassa fever.
Detailed Summary:
Sponsor: U.S. Army Medical Research and Materiel Command
Current Primary Outcome: Adverse reactions [ Time Frame: 5 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: U.S. Army Medical Research and Materiel Command
Dates:
Date Received: June 24, 2015
Date Started: August 2016
Date Completion: June 2019
Last Updated: March 28, 2017
Last Verified: March 2017